Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 380

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone

Open access
Brown, Karen T., Do, Richard K., Gonen, Mithat, Covey, Anne M., Getrajdman, George I., Sofocleous, Constantinos T., Jarnagin, William R., D’Angelica, Michael I., Allen, Peter J., Erinjeri, Joseph P., Brody, Lynn A., O’Neill, Gerald P., Johnson, Kristian N., Garcia, Alessandra R., Beattie, Christopher, Zhao, Binsheng, Solomon, Stephen B., Schwartz, Lawrence H., DeMatteo, Ronald, Abou-Alfa, Ghassan K. · 2016 · Journal of Clinical Oncology

Abstract

Purpose: Transarterial chemoembolization is accepted therapy for hepatocellular carcinoma (HCC). No randomized trial has demonstrated superiority of chemoembolization compared with embolization, and the role of chemotherapy remains unclear. This randomized trial compares the outcome of embolization using microspheres alone with chemoembolization using doxorubicin-eluting microspheres. Materials and Methods: At a single tertiary referral center, patients with HCC were randomly assigned to embolization with microspheres alone (Bead Block [BB]) or loaded with doxorubicin 150 mg (LC Bead [LCB]). Random assignment was stratified by number of embolizations to complete treatment, and assignments were generated by permuted blocks in the institutional database. The primary end point was response according to RECIST 1.0 (Response Evaluation Criteria in Solid Tumors) using multiphase computed tomography 2 to 3 weeks post-treatment and then at quarterly intervals, with the reviewer blinded to treatment allocation. Secondary objectives included safety and tolerability, time to progression, progression-free survival, and overall survival. This trial is currently closed to accrual. Results: Between December 2007 and April 2012, 101 patients were randomly assigned: 51 to BB and 50 to LCB. Demographics were comparable: median age, 67 years; 77% male; and 22% Barcelona Clinic Liver Cancer stage A and 78% stage B or C. Adverse events occurred with similar frequency in both groups: BB, 19 of 51 patients (38%); LCB, 20 of 50 patients (40%; P = .48), with no difference in RECIST response: BB, 5.9% versus LCB, 6.0% (difference, −0.1%; 95% CI, −9% to 9%). Median PFS was 6.2 versus 2.8 months (hazard ratio, 1.36; 95% CI, 0.91 to 2.05; P = .11), and overall survival, 19.6 versus 20.8 months (hazard ratio, 1.11; 95% CI, 0.71 to 1.76; P = .64) for BB and LCB, respectively. Conclusion: There was no apparent difference between the treatment arms. These results challenge the use of doxorubicin-eluting beads for chemoembolization of HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.64.0821

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 380

Metadata

Authors
Brown, K. T., Do, R. K., Gonen, M., Covey, A. M., Getrajdman, G. I., Sofocleous, C. T., Jarnagin, W. R., D’Angelica, M. I., Allen, P. J., Erinjeri, J. P., Brody, L. A., O’Neill, G. P., Johnson, K. N., Garcia, A. R., Beattie, C., Zhao, B., Solomon, S. B., Schwartz, L. H., DeMatteo, R., & Abou-Alfa, G. K.
Venue
Journal of Clinical Oncology
Published
2016-06-10
Volume
34
Issue
17
Pages
2046-2053
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2271921187
Cited by
380
References
21
FWCI
30.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. https://app.cochat.ai/papers/10.1200/jco.2015.64.0821
The paper
Brown, K. T., Do, R. K., Gonen, M., Covey, A. M., Getrajdman, G. I., Sofocleous, C. T., Jarnagin, W. R., D’Angelica, M. I., Allen, P. J., Erinjeri, J. P., Brody, L. A., O’Neill, G. P., Johnson, K. N., Garcia, A. R., Beattie, C., Zhao, B., Solomon, S. B., Schwartz, L. H., DeMatteo, R., & Abou-Alfa, G. K. (2016). Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.64.0821

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.